Breast Cancer

12 protocols meet the specified criteria.
  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
  • D8531C00002

    CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
  • D926XC00001

    TROPION-Breast03: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-Negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy
  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)
  • NRG-BR009

    A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score </= 25 (OFSET)
  • NSABP-FB12

    An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
  • S1706

    A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
  • S2010

    A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (Aspen)
  • S2013

    Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
  • S2212

    Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
  • WVU010120

    Pioglitazone Therapy Targeting Fatigue in Breast Cancer
  • WVU011115

    Skeletal Muscle Tissue Procurement for the Study of Breast Cancer -Associated Gene Expression